

Relationship Between Polymorphism in Promoter Region of E-Cadherin (Cdh1) Gene and Helicobacter Pylori Infection in Kurdish Population of Iran

Abbas Ahmadi¹, Farid Zandi², Alireza Gharib³, Neda Menbari⁴, Javad Hosseini⁵, Mohammad Abdi⁵, Akbar Jalili⁶,
Mohammad Nazir Menbari^{1*}

¹ Kurdistan Cellular and Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran

² Faculty of Sciences, Department of Biology, Soran University, Kurdistan region-Iraq

³ Deputy of Research and Technology, Kurdistan University of Medical Sciences, Sanandaj, Iran

⁴ Department of Veterinary, Razi University, Kermanshah, Iran

⁵ Department of Clinical Biochemistry, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

⁶ Department of Science, Ahar Branch, Islamic Azad University- Ahar- Iran

*Corresponding Author : nazir.nazir.33@gmail.com

Abstract: Infection with *Helicobacter pylori* (*H. pylori*) in addition to inflammation in gastric mucosa and much mortality may progress to gastric cancer. Gastric cancers like many other cancers have a multistage process and cause obvious changes in environmental, genetic and epigenetic factors. Polymorphism in promoter region of CDH1 gene has been associated with reduced E-cadherin protein expression. It has been proposed that *H. pylori* infection may cause multiple nucleotide changes in CDH1 gene. **Aimed:** We evaluated the association between -160 (C>A) CDH1 gene polymorphism with *H. pylori* infection in Kurdish population. **Methods:** A total of 162 biopsies taken from non-ulcer dyspepsia patients were classified as *H.pylori* infected and *H.pylori* uninfected. All previous diagnoses confirmed pathologically and molecularly. Polymorphism in -160(C>A) CDH1 was evaluated by PCR-RFLP. **Results:** Infection with *H. pylori* was found in 67% of patients. *H. pylori* infection was more frequently found in biopsies with the -160C/A genotype than those with the -160C/C (*P* value = 0.01). **Conclusion:** 160C/A genotype might require *H. pylori* infection to promote the inactivation of CDH1. This suggests that *H. pylori* infection might affect gastric cancer (GC) in an initial stage.

[Abbas Ahmadi, Farid Zandi, Alireza Gharib, Neda Menbari, Javad Hosseini, Mohammad Abdi, Akbar Jalili, Mohammad Nazir Menbari, **Relationship Between Polymorphism in Promoter Region of E-Cadherin (Cdh1) Gene and Helicobacter Pylori Infection in Kurdish Population of Iran.** *Life Sci J* 2013;10(12s): 552-556] (ISSN:1097-8135). <http://www.lifesciencesite.com>. 90

Keywords: E-cadherin, Kurdish population, polymorphism, *Helicobacter pylori*, CDH1 gene

Introduction

E-cadherin (E-cad, also known as CDH1) is a member of a family of transmembrane glycoproteins expressed on epithelial cells and is responsible for calcium-dependent cell-to-cell adhesion[1]. E-cad forms complexes and connects actin filaments with α -, β -, and γ -catenins[2,3], which is crucially involved in neoplastic transformation and metastasis[4,5]. Loss of cell adhesion may contribute to loss of contact inhibition of growth, which is an early step in the neoplastic process. Furthermore, loss of cadherin activity may result in cancer cell detachment and metastasis [6,7]. Gastric carcinogenesis is a multistep process with morphological progression involving multiple genetic and epigenetic events, whereas CDH1 is an important putative tumor suppressor gene. In gastric carcinoma (GC), the percentage reduction in E-cad expression varies from 17% to 92%, and is more frequent in diffuse type carcinomas than in intestinal types[8-13]. Germ-line mutation of the CDH1 gene is found in familial GCs[14,15]. Somatic mutations of E-cad are

found in more than 50% of gastric carcinomas of the diffuse type[16-18]. In addition to the classic two-hit inactivation mechanism, CDH1 can be silenced by cytosine-guanosine (CpG) sequence methylation in GC[12,17,18]. Moreover, Li et al., reported that -160C/A polymorphism has a direct effect on the transcriptional regulation of CDH1[21,19]. *Helicobacter pylori* (*H. pylori*) is the single most important etiological factor for gastric cancer development. The strongest evidence comes from three independent, nested case-control studies in which pre-existing infection markedly increased the risk of GC[20-22]. It is estimated that approximately 60% of all GC cases can be attributed to *H. pylori* infection[20]. However, there are few data in the molecular profiles of E-cad of *H. pylori*-positive and *H. pylori*-negative GCs[23]. El-Omar et al.[24], reported that interleukin-1 polymorphisms that cause the up-regulation of interleukin-1 β with *H. pylori* infection are associated with an increased risk of GC. Moreover, Hmadcha et al.[25], found that interleukin-1 β might induce gene methylation

through the production of nitric oxide and the subsequent activation of DNA methyltransferase. It is possible that *H. pylori* infection induces methylation through the production of interleukin-1 β . In this study, we investigated the relationship between *H. pylori* infection and -160C/A polymorphism in germ line, we also investigated the relationship between *H. pylori* infection and polymorphism, to find if *H. pylori* infection affects tumorigenesis in the initial stage.

Subjects and methods

162 Kurdish patients with nonulcer dyspepsia patients who underwent endoscopy in Hospital and cancer center of Kurdistan University of medical sciences, Kurdistan, Iran, were consecutively recruited from 2004 to 2009. All diagnoses were pathologically confirmed. In patients group *H. pylori* infected and uninfected subjects were determined by the RUT, PCR 16srRNA (1) examination of biopsies taken from the corpus. Patients were classified as *H. pylori* -infected only if the two tests were positive and *H. pylori*-uninfected if the two tests were negative, respectively. Demographic and clinical data were obtained from subjects through interview using a standard clinical pro forma. Exclusion criteria included history of nonulcer dyspepsia patients, liver disease, and previous treatment with nonsteroidal anti-inflammatory drugs, proton pump inhibitors, antibiotics, or bismuth salts. Informed consents for participation were signed by all subjects. The study protocol was approved by the Clinical Research Ethics Committee of the Kurdistan University of Medical Sciences.

Histological examination

Sections of biopsy specimens were embedded 10 % buffered formalin and stained with hematoxylin and eosin to examine gastritis and with giemsa to detect *H. pylori* (2). The histological examination of gastric mucosa were blindly performed according to the Updated Sydney system (3)

DNA isolation

DNA of case was extracted from biopsies taken from the corpus using Biospin Tissue genomic DNA Extraction Kit (Bio Flux, Japan). All extracted DNA was resuspended in UltraPure RNase/DNase-Free Distilled water.

Genotyping for -160 (C>A) CDH1 polymorphism

Genotyping analysis of -160 (C>A) CDH1 were performed by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Primer sequences for -160(C>A) variation of CDH1 gene are as follows: sense 5'-TGATCCCAGGTCTTAGTGAG-3', anti-sense 5'-AGTCTGAACTGACTTCCGCA-3'. The PCR amplification was performed in a total volume of 25 μ L mixture containing: 100 ng genomic DNA, 1.0 mM of each primer, 200 mM of each dNTP, 2.0 mM of MgCl₂ and 1.0 U Taq DNA polymerase and 10 X Taq buffer (Fermentas) using the Biometra Tgradient 96 (Biometra, Germany). PCR conditions were as follows: denaturation at 95 oC for 5 min, followed by 35 cycles of 95 oC for 30 s, 58 oC for 30 s, and 72 oC for 30 s. A final extension was carried out at 72 oC for 5 min and cooling down to 4 oC. The PCR products were digested by restriction endonuclease BesEII (Fermentas), according to the manufacturer's instructions, at 37°C overnight and then separated by 3% agarose gel electrophoresis. Gel analysis was performed after staining with ethidium bromide. PCR products were shown to be digested into three types of fragments (Fig. 1). To confirm the genotyping results, selected PCR samples in both groups including samples of each genotype were re-genotyped by other laboratory personnel. There was no difference after sequencing the randomly selected samples.

Statistical analysis

Data were analyzed using SPSS 16.0 (SPSS Inc., Chicago, IL). Hardy-Weinberg equilibrium in all subjects was analyzed with the χ^2 goodness-of-fit test before the ensuing analyses. The confounding




Fig1: PCR-RFLP 3% agarose gel electrophoresis of the -160(C>A) CDH1 polymorphism indicating No.12 (AA = 328 bp) 1, 3, 4, 5, 7, 8, 9, 10, 13, 15, 18 (AC = 328, 218, 110 bp) 2, 6, 11, 14, 16, 17, 19, 20 (CC = 218, 110 bp) genotypes

effects of age and gender were adjusted using conditional logistic regression. Also Statistical analysis was performed by non-paired t-test depending on the data set. Values of $p < 0.05$ were considered as significant

Results

Demographic and clinical characteristics

Genomic DNA was obtained among the 162 nonulcer dyspepsia patients subjects then the DNA all subjects were genotyped. The demographic data of all subjects were demonstrated in Table 1. There was no significant difference between the two groups with respect to the age and gender distribution ($p > 0.05$).

Table 1: Demographic data of study subjects.

Variable	positive (%)	negative (%)
Overall	108 (66.7%)	54(33.3%)
Gender		
Male	60(37%)	27(16.7%)
Female	48(29.6%)	27(16.7%)
Age		
Mean±SD (year)	59.52 ±15	

$p < 0.05$ was considered statistically significant

Of these 162 patients, 87 were men, and 75 were women. Their median age was 59.52 ±15 years. H pylori was found in 66.6% of patients and was not found in 33.4% of patients

H. pylori and -160C/A polymorphism

Among the 162 patients, 104 were genotype C/C (64.2%), 56 were genotype A/C (34.6%), and 2 were genotype A/A (1.2%). Interestingly, analyzing 162 available patients of H .pylori infection and H.pylori-uninfected polymorphism status, H. pylori infection was frequently observed in patients with C/A genotype more than in patients CC genotype patients($P = 0.01$).

Table 2. 95% confidence intervals (CIs) for -160(C>A) CDH1 polymorphism and susceptibility to H.pylori infection

Genotypes of CDH1	H.pylori-infected (%)	H.pylori-uninfected (%)	#P value
case			
AA*	1(0.6%)	1(0.6%)	
AC	46(28.8%)	9(5.8%)	
CC	59(36.5%)	45(27.7%)	0.01

*The sample size of **AA** was small so it was not statistically significant.

$p < 0.05$ was considered statistically significant.

Evaluation of -160(C>A) polymorphism and susceptibility to Helicobacter pylori infection according to sex. -160(C>A) CDH1 polymorphism was evaluated in both sexes for H. pylori infected and non-infected cases (Table 3). Then Polymorphisms of -160(C>A) CDH1 were compared in H. pylori infected and non-infected cases in both groups without any significant ($p = 0.504$).

Table 3 .Evaluation of -160(C>A) polymorphism and susceptibility to Helicobacter pylori infection according to sex

Variable	H.pylori infected (%)	H.pylori uninfected (%)	#P value
Overall	108 (66.7%)	54(33.3%)	
Gender			
Male	60(37%)	27(16.7%)	0.504
Female	48(29.6%)	27(16.7%)	

$p < 0.05$ was considered statistically significant.

Discussion

CDH1 gene located on chromosome 16 (1/22 q 16). The role of this gene is expression cellular adhesion proteins on epithelial cells. E-cadherin protein that resulting from expression of CDH1 gene, acts as a tumor suppressor (4) . Mutations and impaired function of this gene has been found in gastric cancer[11]. There is no data regarding CDH1 gene polymorphism on Helicobacter pylori (H.pylori) infection among Kurdish population till date. Since the CDH1 gene may play a major role in the development of gastric cancer and nonulcer dyspepsia patients, we studied polymorphism in the region promoter, -160 (C > A), of CDH1 gene to evaluate whether this polymorphism can affect the CDH1 gene in this population with nonulcer dyspepsia patients. In the present study we found that frequencies of -160(C>A) CDH1 genotypes were comparable in H.pylori-infected and H.pylori - uninfected subjects in These findings suggest that -160 (C>A) CDH1 polymorphism have relate with H.pylori infection susceptibility. H. pylori is responsible for the pathogenesis of atrophic gastritis and intestinal metaplasia[30,31]. Epidemiological studies have indicated that infection with H. pylori is a risk factor for GC[20,22,26]. Moreover, Mongolian gerbils develop chronic gastritis, intestinal metaplasia, and adenocarcinoma after inoculation with H. pylori into the stomach. However, the link between H. pylori infection and the molecular mechanism of human gastric carcinoma remains to be investigated. Lim et al., reported that the increased expression of cell adhesion molecules (galectin 1, aldolase A, integrin $\alpha 5$, LMO7) and the decrease in

E-cad expression induced by *H. pylori* might contribute to cell adhesion, invasion, and possibly cell proliferation in gastric epithelial cells[32,29]. Kitadai et al., reported that coculture with *H. pylori* increased the expression of interleukin-8, vascular endothelial growth factor (VEGF), angiogenin, uPA, and MMP-9 and increased angiogenic and collagenase activities in gastric carcinoma cells[33]. Sharma et al., reported that the activation of interleukin-8 gene expression by *H. pylori* is regulated by the transcription factor, nuclear factor-kappa B, in gastric epithelial cells[34]. Akhtar et al., reported that promoter methylation regulates *H. pylori*-stimulated cyclooxygenase-2 expression in gastric epithelial cells[35, 36]. However, in vivo data on the differences in the molecular profile (ras, MDM2,c-erbB-2, cyclin D1, p53, CDH1) of *H. pylori*-positive and *H. pylori*-negative gastric carcinomas are almost non-existent[23,27,28]. In this study, *H. pylori* was found in 67% of patients with nonulcer dyspepsia. This is consistent with the current view that 60% of all GC cases are related to *H. pylori* infection, irrespective of the histological tumor type[20,23].

***H. pylori* and promoter polymorphism**

Li et al., reported that the A allele of the -160C/A promoter polymorphism altered transcriptional binding, resulting in a reduction in transcriptional efficiency of 68% relative to that of the C allele[19]. In this study, *H. pylori* was significantly more frequent in the C/C genotype of CDH1 promoter than in the C/A+A/A genotypes. The C allele shows better transcriptional activity than the A allele, so patients with the C/C type may require *H. pylori* infection to promote the inactivation of CDH1. Since -160C/A polymorphism is germ line, *H. pylori* infection might affect CDH1 inactivation in an early, possibly preneoplastic stage. Therefore, *H. pylori* infection should be considered as a factor that facilitates a multifactorially determined process of gastric carcinogenesis in an initial stage. Finally, we must acknowledge that the CDH1 gene polymorphism at position -160(C-->A) has a various outcomes in different ethnic groups and geographic locations. This polymorphism should be evaluated with other environmental factors simultaneously. Therefore, further studies are needed to confirm our findings.

Acknowledgements

We thank the department of immunology and microbiology and Cellular & Molecular Research Center, Kurdistan University of Medical Sciences.

References

1. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. *Science* 1991; 251: 1451–1455
2. Takeichi M. Cadherins. A molecular family important in selective cell–cell adhesion. *Annu Rev Biochem* 1990; 59:237–252
3. Grunwald G. The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. *Curr Opin Cell Biol* 1993; 5: 797–805
4. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. *Am J Pathol* 1998; 153:333–339
5. Pignatelli M, Vessey CJ. Adhesion molecules: novel molecular tools in tumor pathology. *Hum Pathol* 1994; 25: 849–856
6. Hashimoto M, Niwa O, Nitta Y, Takeichi M, Yokoro K. Unstable expression of E-cadherin adhesion molecules in metastatic ovarian tumor cells. *Jpn Cancer Res* 1989; 80: 459–463
7. Bussemakers MJ, van Moorselaar RJ, Girolodi LA, Ichikawa T, Isaacs JT, Takeichi M, Debruyne FM, Schalken JA. Decreased expression of E-cadherin in the progression of rat prostatic cancer. *Cancer Res* 1992; 52: 2916–2922
8. Shimoyama Y, Hirohashi S. Expression of E- and P-cadherin in gastric carcinomas. *Cancer Res* 1991; 51: 2185–2192
9. Chong S, Lou Q, Fitzgerald JF, Lee C-H. Evaluation of 16S rRNA gene PCR with primers Hp1 and Hp2 for detection of *Helicobacter pylori*. *Journal of clinical microbiology*. 1996;34(11):2728-30
10. Machado JC, Oliveira C, Carvalho R, Soares P, Berx G, Caldas C, et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. *Oncogene*. 2001 Mar 22;20(12):1525-8.
11. Berx G, Becker KF, Hofler H, van Roy F. Mutations of the human E-cadherin (CDH1) gene. *Hum Mutat*. 1998;12(4):226-37.
12. Gabbert HE. Mechanisms in tumor invasion: evidence from *in vivo* observations. *Cancer Metastasis Rev* 1985; 4: 293–309
13. Shun CT, Wu MS, Lin JT, Wang HP, Houg RL, Lee WJ, Wang TH, Chuang SM. An immunohistochemical study of E-cadherin expression with correlations to clinicopathological features in gastric cancer. *Hepatogastroenterology* 1998; 45:944–999
14. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE. E-cadherin germline mutations in familial gastric cancer. *Nature* 1998;92: 402–405
15. Gayther SA, Goringe KL, Ramus SJ, Huntsman D, Roviello F, Grehan N, Machado JC, Pinto E, Seruca R, Halling K, MacLeod P, Powell SM, Jackson CE, Ponder BA, Caldas C. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. *Cancer Res* 1998; 58: 4086–4089
16. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Hofler H. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. *Cancer Res* 1994; 54: 3845–3852

17. Machado JC, Oliveira C, Carvalho R, Soares P, Bex G, Caldas C, Seruca R, Carneiro F, Sobrinho-Simoes M. E-cadherin gene (*CDH1*) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. *Oncogene* 2001; 20: 1525–1528
18. Chan AO, Lam SK, Wong BC, Wong WM, Yuen MF, Yeung YH, Hui WM, Rashid A, Kwong YL. Promoter methylation of *E-cadherin* gene in gastric mucosa associated with *Helicobacter pylori* infection and in gastric cancer. *Gut* 2003; 52: 502–506
19. Li LC, Chui RM, Sasaki M. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. *Cancer Res* 2000; 60: 873–876
20. Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, Sitas F. Association between infection with *Helicobacter pylori* and risk of gastric cancer. *BMJ* 1991; 302: 1302–1305
21. Nomura A, Stemmerman G, Chyou MJ, Kato I, Perez-Perez G, Blaser M. *Helicobacter pylori* infection and gastric carcinoma 1991; 325: 1132–1136
22. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. *elicobacter pylori* infection and the risk of gastric carcinoma. *N Engl J Med* 1991; 325: 1170–1171
23. Blok P, Craanen ME, Offerhaus GJ, Dekker W, Kuipers EJ, Meuwissen SG, Tytgat GN. Molecular alterations in early gastric carcinomas. *Am J Clin Pathol* 1999; 111: 241–247
24. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* 2000; 404: 398–402
25. Hmadcha A, Bedoya FJ, Sobrino F, Pintado E. Methylationdependent gene silencing induced by interleukin 1 β via nitric oxide production. *J Exp Med* 1999; 190: 1595–1604
26. Moskaluk CA, Kern SE. Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. *Am J Pathol* 1997; 150: 1547–1552
27. Lauren P. The two main histological types of gastric carcinoma diffuse and so-called intestinal type of carcinoma. *Acta Pathol Microbiol Scand* 1965; 64: 31–49
28. Sobin LH, Wittekind CH (editors). International union against cancers (UICC): TNM classification of malignant tumors. 5th ed. *New York: John Wiley* 1997
29. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylationstatus of CpG islands. *Proc Natl Acad Sci USA* 1996; 93: 9821–9826
30. Graff JR, Herman JG, Myöhänen S, Baylin SB, Vertino PM. Mapping patterns of CpG island methylation in normal andneoplastic cells implicates both upstream and downstreamregions in *de Novo* methylation. *J Biol Chem* 1997; 272: 22322–22329
31. Kawaguchi H, Haruma K, Kohmoto K, Yoshihara M, Sumii K, Kajiyama G. *Helicobacter pylori* infection is the major risk factor for atrophic gastritis. *Am J Gastroenterol* 1996; 91:959–962
32. Lim JW, Kim H, Kim KH. Cell adhesion-related gene expression by *Helicobacter pylori* in gastric epithelial AGS cells. *Int J Biochem Cell Biol* 2003; 35: 1284–1296
33. Kitadai Y, Sasaki A, Ito M, Tanaka S, Oue N, Yasui W, Aihara M, Imagawa K, Haruma K, Chayama K. *Helicobacter pylori* infection influences expression of genes related toangiogenesis and invasion in human gastric carcinoma cells. *Biochem Biophys Res Commun* 2003; 311: 809–814
34. Sharma SA, Tummuru MK, Blaser MJ, Kerr LD. Activation of IL-8 gene expression by *Helicobacter pylori* is regulated by transcription factor, nuclear factor-kappa B in gastric epithelial cells. *J Immunol* 1998; 160: 2401–2407
35. Akhtar M, Cheng Y, Magno RM, Ashktorab H, Smoot DT, Meltzer SJ, Wilson KT. Promoter methylation regulates *Helicobacter pylori* stimulated cyclooxygenase-2 expression in gastric epithelial cells. *Cancer Res* 2001; 61: 2399–2403
36. Menbari MN, Rahmani SA, Ahmadi A, Zandi F, Bagheri N, Jalili A, et al. Evaluation of E-cadherin (CDH1) Gene Polymorphism Related To Gastric Cancer In Kurdish Population. *Life Science Journal*. 2013;10(12s)